Published by Pinnacle Pulse, maker of a self-tracking app. We have no affiliate or sales relationship with any peptide seller. Editorial policy →
Is BPC-157 legal? Status in the EU, the US and in sport
By Pinnacle Pulse Editorial Team · Status as of 16 October 2026 · Next scheduled update: 14 January 2027
Short answer: BPC-157 is not an authorized medicine in the EU or in the US. In the US it sits on neither of FDA’s compounding lists; an advisory committee voted on it in July 2026, but no rule has followed. In sport, WADA names it under class S0, prohibited at all times. This page is general information, not legal advice.
At a glance
| Where | Status on 16 October 2026 |
|---|---|
| EU | No marketing authorization; no entry in EMA’s medicines data |
| US | Not FDA-approved; not on the 503A bulks categories; July 2026 advisory vote is non-binding, no proposed rule |
| WADA | Named in class S0 (non-approved substances), prohibited in and out of competition |
European Union
There is no EU-wide authorization for a BPC-157 medicine. It doesn’t appear in EMA’s medicines data.
The tricky part is whether a vial marked “research chemical, not for human use” is a medicine at all. EU law looks at how a product is presented and what it does, not at whatever the seller prints on the label.
United States
FDA has never approved a drug containing BPC-157.
The live US question is about compounding pharmacies, which may only use bulk substances that meet certain conditions. While FDA evaluates nominated substances for the 503A bulks list, it sorts them into categories. BPC-157 sat in Category 2, the group flagged for significant safety risks. In April 2026 the nominations were withdrawn and FDA took it off the category lists. FDA’s page of withdrawn substances spells out its worries: possible immune reactions, impurities and trouble characterizing the active ingredient, and little or no human safety information.
FDA put BPC-157 in front of its Pharmacy Compounding Advisory Committee anyway, on 23 July 2026, evaluated for ulcerative colitis. In the briefing document, FDA staff recommended against adding it. The committee was then asked to vote on whether BPC-157 belongs on the list. FDA hasn’t posted the result on its meeting page, and advisory votes don’t bind the agency anyway. As of 16 October 2026 no proposed rule has appeared in the Federal Register. There is one new item, though: OMB’s list of regulatory actions under review shows that on 14 October 2026 it received an FDA notice titled “Interim Access Policy for Compounding Using Certain Peptides”. What it says isn’t public yet.
None of this touches products sold online as research chemicals. Compounding rules apply to licensed pharmacies filling prescriptions.
Sport
WADA’s 2027 Prohibited List, valid from 1 January 2027, names BPC-157 in class S0 (non-approved substances). S0 catches substances not covered elsewhere on the list and not approved by any health authority for human therapeutic use, and the 2027 list now gives peptides as an example. It’s banned in and out of competition. S0 substances count as “specified”, which affects how sanctions are calculated, not whether the substance is banned.
What the research does not show
A legal status isn't a verdict on whether something works or is safe. The July 2026 vote didn't rest on new clinical evidence. No randomized controlled trial of BPC-157 is indexed in PubMed, and FDA's own staff pointed to missing human safety data. Our article [BPC-157: what the research shows](/research/bpc-157) goes through the studies.FAQ
Is BPC-157 legal in the EU?
It is not an authorized medicine in the EU, and EMA’s medicines data have no entry for it. Whether a particular product counts as a medicine depends on how it is presented and what it does, not on the label, so check your own case with a lawyer.
Is BPC-157 legal in the US?
It is not FDA-approved and not on the lists of substances compounding pharmacies may use. A July 2026 advisory committee vote is non-binding, and FDA had not published a proposed rule as of 16 October 2026.
Is BPC-157 banned in sport?
Yes. WADA names BPC-157 in class S0 of the Prohibited List, so it is banned at all times for athletes covered by anti-doping rules.
Did FDA approve BPC-157 in 2026?
No. An advisory committee voted on whether compounding pharmacies may use it. That vote does not approve a drug, and FDA has published no rule on it.
Sources
- FDA. Bulk drug substances nominated for use in compounding under section 503A: categories. fda.gov/media/94155/download
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov (checked 16 October 2026)
- FDA. FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026. fda.gov/media/193342/download
- WADA. WADA publishes 2027 Prohibited List (21 September 2026). wada-ama.org
- WADA. The Prohibited List. wada-ama.org
- USADA. Athlete advisory: what’s new on the 2027 WADA Prohibited List? usada.org
- EMA. Download medicine data: table of all medicines assessed by EMA (Excel), checked 16 October 2026. ema.europa.eu
- FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: questions for the committee (PDF), checked 16 October 2026. fda.gov/media/193711/download
- FDA. Briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 2026, checked 16 October 2026. fda.gov/media/193343/download
- Federal Register. Search of FDA documents published since 1 April 2026 for BPC-157, TB-500 and the 503A and 503B bulks lists, run 16 October 2026: no proposed or final rule. federalregister.gov
- Office of Information and Regulatory Affairs (OMB). Regulatory review list: FDA notice “Interim Access Policy for Compounding Using Certain Peptides”, received 14 October 2026, checked 16 October 2026. reginfo.gov
- PubMed search “BPC-157 AND (randomized controlled trial[pt] OR clinical trial[pt])”, run 16 October 2026 via NCBI E-utilities: 0 records.
- WADA. 2027 Prohibited List, full text (PDF), checked 16 October 2026. wada-ama.org
Facts last checked: 16 October 2026.
About this article
Written by: the Pinnacle Pulse Editorial Team, the people who make the Pinnacle Pulse app. We work only from primary sources such as regulators, legal texts, trial registries and PubMed, and we remove claims we can’t check against one.
This page has not been reviewed by a lawyer. It is general information, not legal advice.
Spotted an error? Our editorial policy explains how to report it and how we correct mistakes.
Change log
- 16 October 2026: First published.
From the makers of this site: Pinnacle Pulse is a neutral tracking app. We don’t sell or recommend any substance. About Pinnacle Pulse
This page is general information about the law as of the date shown. It is not legal advice. For your own situation, consult a lawyer.